3-(吡啶-2-基)-5-(3,5-二氯苯基)-1,2,4-噁二唑 | 327056-07-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 3-(吡啶-2-基)-5-(3,5-二氯苯基)-1,2,4-噁二唑
• 英文名称: 3-(pyridin-2-yl)-5-(3,5-dichlorophenyl)-1,2,4-oxadiazole
• 英文别名: 3-(2-pyridyl)-5-(3,5-dichlorophenyl)-1,2,4-oxadiazole；2-[5-(3,5-Dichlorophenyl)-1,2,4-oxadiazol-3-yl]pyridine；5-(3,5-dichlorophenyl)-3-pyridin-2-yl-1,2,4-oxadiazole
• CAS: 327056-07-5
• 化学式: C₁₃H₇Cl₂N₃O
• 分子量: 292.124
• InChiKey: HSLAPYCDJGEODS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  51.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3,5-二氯苯甲酸 在 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 生成 3-(吡啶-2-基)-5-(3,5-二氯苯基)-1,2,4-噁二唑
  参考文献：
  名称：

  Discovery and characterization of AZD9272 and AZD6538—Two novel mGluR5 negative allosteric modulators selected for clinical development

  摘要：

  AZD9272 and AZD6538 are two novel mGluR5 negative allosteric modulators selected for further clinical development. An initial high-throughput screening revealed leads with promising profiles, which were further optimized by minor, yet indispensable, structural modifications to bring forth these drug candidates. Advantageously, both compounds may be synthesized in as little as one step. Both are highly potent and selective for the human as well as the rat mGluR5 where they interact at the same binding site than MPEP. They are orally available, allow for long interval administration due to a high metabolic stability and long half-lives in rats and permeate the blood brain barrier to a high extent. AZD9272 has progressed into phase I clinical studies. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.08.100

文献信息

• Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
  申请人：——

  公开号：US20030055085A1

  公开（公告）日：2003-03-20

  The present invention provides compounds and pharmaceutical compositions that act as antagonists at metabotropic glutamate receptors, and that are useful for treating neurological diseases and disorders. Methods of preparing the compounds also are disclosed.

  本发明提供了作为代谢型谷氨酸受体拮抗剂的化合物和药物组合物，用于治疗神经系统疾病和障碍。还公开了制备这些化合物的方法。
• Treatment of neuromuscular dysfunction of the lower urinary tract with selective mGlu5 antagonists
  申请人：Recordati S.A.

  公开号：US20040215284A1

  公开（公告）日：2004-10-28

  The invention is directed to methods of using antagonists selective for the metabotropic mGlu5 receptor to treat conditions of neuromuscular dysfunction of the lower urinary tract in a mammal. Provided are methods of treating a mammal suffering from a condition of neuromuscular dysfunction of the lower urinary tract by administering a selective mGlu5 antagonist. The selective mGlu5 antagonist may be administered alone or in combination with one or more additional therapeutic agent for treating such a condition. Also provided are methods of identifying selective mGlu5 antagonists that are useful for treating neuromuscular dysfunction of the lower urinary tract in a mammal.

  本发明涉及使用选择性代谢型mGlu5受体拮抗剂治疗哺乳动物下尿路神经肌肉功能障碍的方法。本发明提供了通过施用选择性 mGlu5 拮抗剂来治疗患有下尿路神经肌肉功能障碍的哺乳动物的方法。选择性 mGlu5 拮抗剂可单独给药或与一种或多种额外的治疗剂联合给药，以治疗这种病症。还提供了鉴定选择性mGlu5拮抗剂的方法，这些选择性mGlu5拮抗剂可用于治疗哺乳动物的下尿路神经肌肉功能障碍。
• HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS
  申请人：NPS PHARMACEUTICALS, INC.

  公开号：EP1210344A1

  公开（公告）日：2002-06-05
• SELECTIVE MGLU5 ANTAGONISTS FOR TREATMENT OF NEUROMUSCULAR DYSFUNCTION OF THE LOWER URINARY TRACT
  申请人：Recordati Ireland Limited

  公开号：EP1599204A2

  公开（公告）日：2005-11-30
• NEW USE
  申请人：AstraZeneca AB

  公开号：EP1896011A1

  公开（公告）日：2008-03-12